31 October 31 2006 - Kyoto
New data shows that Stalevo significantly improves quality of life in patients with Parkinson’s disease with no or minimal motor fluctuations, when compared to traditional levodopa therapy. In addition, new analysis suggests that patients treated earlier with enhanced levodopa therapy including entacapone experienced a sustained improvement in symptom control that was not achieved when treatment was delayed by 6 months.
The new findings were presented today at the 10th International Congress of Movement Disorders Society (MDS) of Parkinson’s Disease in Kyoto, Japan.
